Aurinia Pharmaceuticals Inc Stock News

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective an

The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positi

GENEVA--(BUSINESS WIRE)--Lucien Selce, who owns approximately 2.2% of the outstanding shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the follo

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference.

AUPH reports Q1'24 net product revenues of $48.1M, representing a 13.6% increase from the previous quarter. AUPH's pipeline member AUR200 has not been shelved and could enter phase 1 studies in 2024 w

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & Investor Relations Peter

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.18 per share a year ago.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives

Aurinia Pharmaceuticals Inc. full-year 2023 sales of Lupkynis increased by 53% year over year to $158.5 million. Updated label provides several advantages for sales of Lupkynis going forward, like no

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Progra

Aurinia Pharmaceuticals has the potential for up to 80-100% upside by the end of 2024. The company's focus on cost savings and a single product commercial biotech strategy is positive. The potential i

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference.